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Objective: Vascular access dysfunction is a major problem in hemodialysis patients. Only 50% of arteriovenous grafts
(AVGs) will remain patent 1 year after surgery. AVGs frequently develop stenoses and occlusions at the venous
anastomoses in the venous outflow tract. Lumen diameter is not only determined by intimal thickening but is also
influenced by remodeling of the vessel wall. Vascular remodeling requires degradation and reorganization of the
extracellular matrix by the degradation enzymes, matrix metalloproteinases (MMPs). In this study, we aimed to provide
further insight into the mechanism of endothelial regulation of vascular remodeling and luminal narrowing in AVGs.
Methods: End-to-side carotid artery–jugular vein polytetrafluoroethylene grafts were created in 20 domestic swine. The
anastomoses and outflow vein were treated with Gelfoam matrices (Pfizer, New York, NY) containing allogeneic porcine
aortic endothelial (PAE, n  10) cells or control matrices without cells (n  10), and the biologic responses to PAE
implants were investigated 3 and 28 days postoperatively. Angiograms before euthanasia were compared with baseline
angiograms. Tissue sections were stained with hematoxylin and eosin, Verhoeff elastin, and antibodies specific toMMP-9
and MMP-2 and underwent histopathologic, morphometric and immunohistochemical analysis.
Results: Veins treated with PAE cell implants had a 2.8-fold increase in venous lumen diameter compared with baseline
(P < .05), a 2.3-fold increase in lumen diameter compared with control, and an 81% decrease in stenosis (P < .05)
compared with control at 28 days. The increase in lumen diameter by angiographic analysis correlated withmorphometric
analysis of tissue sections. PAE implants increased the venous lumen area 2.3-fold (P < .05), decreased venous luminal
occlusion 66%, and increased positive venous remodeling 1.9-fold (P < .05) compared with control at 28 days. PAE cell
implants reduced MMP-2 expression and neovascularization at 3 and 28 days and adventitial fibrosis at 28 days,
suggesting a role of the implants in controlling the affects of medial and adventitial cells in the response to vascular injury.
Conclusions: These results demonstrate that the adventitial application of endothelial implants significantly reduced
MMP-2 expression within the venous wall, and increased venous lumen diameter and positive remodeling in a porcine
arteriovenous graft model. Adventitial endothelial implants may be useful in decreasing luminal narrowing in a clinical
setting. (J Vasc Surg 2007;46:548-56.)
Clinical Relevance: Vascular access dysfunction is the leading cause of hospitalization and morbidity in patients
receiving hemodialysis for end-stage renal disease. Data indicate that most arteriovenous grafts fail due to the
formation of stenosis at the vein-graft anastomotic and venous outflow sites. The stenoses result in luminal
narrowing and subsequent graft thrombosis and failure. A satisfactory long-term pharmacologic means of prevent-
ing stenosis due to intimal hyperplasia and negative remodeling in hemodialysis grafts has yet to be found. In a large
animal model of arteriovenous grafts, we show that placement of an adventitial endothelial implant significantly
increased venous lumen diameter at 28 days.Vascular access failure is the major complication in pro-
viding care to patients receiving hemodialysis therapy.1 Al-
though an autogenous fistula is the recommendedmethod to
obtain vascular access, arteriovenous grafts (AVGs) are still a
predominant type of access used in the United States (US),
especially for those patients with a previously failed fistula.
AVGs created for vascular access have a primary patency rate of
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sia has been attributed to smooth muscle cell (SMC) mi-
gration from the media into the intima combined with
platelet and leukocyte activation and subsequent extracel-
lular matrix deposition at the lumen side. It has recently
become evident, however, that adventitial thickening, fi-
brosis, inflammation, and neovascularization also contrib-
ute to lesion formation, negative remodeling, and lumen
loss after experimental vascular injury.7-10 In this paradigm,
vascular injury elicits a cascade that begins with the prolif-
eration of adventitial fibroblasts, their differentiation into
myofibroblasts, secretion and activation of matrix metallo-
proteinases (MMPs), and cell migration from the adventitia
and media to the intima. The adventitia is therefore a
potential therapeutic target for AVG failure. Placement of
allogeneic endothelial implants onto the adventitial sur-
faces of injured vessels effectively diminished intimal thick-
ening after angioplasty and the creation of arteriovenous
fistulas.11-13
In the present study, we investigated the vascular re-
sponses to injury at the lumen, media, and adventitia of
AVGs treated with perivascular allogeneic endothelial im-
plants. We hypothesized that placement of endothelial
implants, which have been shown to produce normal en-
dothelial inhibitory compounds in vitro, onto the adventi-
tia of venous anastomotic and outflow sites could increase
positive or expansive venous remodeling and decrease lu-
minal narrowing. We now report that the application of
endothelial implants to the adventitia of AVGs significantly
reduced angiographic vascular stenoses and increased his-
tologic measures of venous lumen and total vessel areas 28
days after surgery. Furthermore, endothelial implants also
reduced MMP-2 expression, adventitial fibrosis, and neo-
vascularization compared with control.
METHODS
Formulation and testing of endothelial implants.
Porcine aortic endothelial (PAE) cells (Cell Applications,
SanDiego, Calif) were cultured andmaintained in Gelfoam
matrices (Pfizer, New York, NY) as previously described.11
Sterile Gelfoam blocks (4.0 1.0 0.3 cm3) were seeded
with 1.25 to 1.66 105 cells/cm3 and incubated for about
2 weeks until confluent in Endothelial Basal Media (Lonza,
Portsmouth, NH) supplemented with 5% fetal bovine se-
rum (FBS) and 50 g/mL gentamicin. Confluence was
determined by periodic evaluation of cell number after
enzymatic digestion.11
PAE cells were implanted after confluence was
achieved. The production of heparan sulfate (HS), trans-
forming growth factor-1 (TGF-1), nitric oxide (NO),
and tissue inhibitors of metalloproteinases 1 and 2
(TIMP-1 and TIMP-2) by PAE cells cultured in Gelfoam
matrices were used as markers of cell function. HS levels in
conditionedmedia were determined using a dimethylmeth-
ylene blue binding assay. Concentrations of TGF-1,
TIMP-1, and TIMP-2 were determined by enzyme-
linked immunosorbent assay (ELISA; R&D Systems,
Minneapolis, Minn). Total NO levels were determinedindirectly in an ELISA assay (R&D Systems) based on
the Greiss reaction. Control Gelfoam matrices that did
not contain cells were incubated for up to 2 weeks in
medium containing 5% FBS before implantation.
Placement of arteriovenous grafts. The ability of the
endothelial implants to reduce stenosis and lumen loss
when wrapped around AVGs was assessed in an established
porcine AVG model.14 This study conformed to the US
Department of Agriculture regulations and National Re-
search Council guidelines and to the guidelines specified in
the National Institutes of HealthGuide for Care and Use of
Laboratory Animals. The Institutional Animal Care and
Use Committees of Duke University Medical Center
(Durham, NC) approved the study.
The study used 20 male and female domestic Yorkshire
pigs weighing 34 kg  0.9 kg and 10 to 12 weeks of age
(Wesley Looper Farm, Hickory, NC). The pigs received
650mg aspirin 48 and 24 hours before surgery and 325mg
daily until the end of the study. All animals received intra-
venous (IV) dexamethasone (0.5 mg/kg) before surgery to
minimize inflammation in the neck. Anesthesia was in-
duced with Telazol (4.4 mg/kg; Wyeth, Madison, NJ),
ketamine (2.2 mg/kg), glycopyrrolate (0.2 mg/mL),
acepromazine maleate (10 mg/mL), and thiopental 2.5%
(0.22 mL/kg). The pigs were intubated and anesthesia was
maintained with isoflurane inhalant (0.5% to 2%) delivered
through a volume-regulated ventilator. Intravenous hepa-
rin was administered before graft surgery as a 100 U/kg
bolus. Additional bolus doses of heparin were administered
as necessary to maintain an activated coagulation time
(ACT) 200 seconds. All pigs received intramuscular bu-
prenorphine (0.03 mg/kg) immediately after surgery.
Bilateral 8-cm neck incisions were made over the ster-
nocleidomastoid muscle on each side of the neck. A 6-mm
internal diameter polytetrafluoroethylene graft (Atrium
Medical Corp, Hudson, NH) with an average length of
18.6  0.9 cm was tunneled in a subcutaneous tract
between the two incisions. Oblique end-to-side anastomo-
ses were made between the jugular vein and graft and the
carotid artery and graft using 6-0 Prolene suture (Ethicon,
Somerville, NJ).
After completion of the anastomoses, the graft was
percutaneously cannulated just distal to the carotid artery–
graft anastomosis. The venous anastomosis and outflow
tract were imaged using 10 to 15 mL of full-strength
Renografin (Bracco Diagnostics Inc, Princeton, NJ) and an
OEC 9600 C-arm fluoroscope in two planes with 90°
offsets. The anastomoses were then wrapped with two
Gelfoammatrices containing PAE cells (n 10) or no cells
(n 10), covering about 0.5 cm of graft and vessel equally
(Fig 1). Each proximal venous segment was also treated
with one matrix containing PAE cells or no cells by placing
the matrix longitudinally along the length of the vein,
starting at the anastomotic site (Fig 1), thereby covering an
additional 3 to 4 cm of outflow vein.
Gelfoam is an approved gelatin-based surgical sponge
that is commonly used in vascular access procedures as an
adjunct to hemostasis. Gelfoam causes little cellular infiltra-
edia
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it. Empty Gelfoammatrices were used as the control vehicle
in this study.
Graft patency was confirmed weekly throughout the
study by Doppler ultrasound imaging. Cine angiography
was performed just prior to euthanasia as described above.
Percent stenosis was calculated quantitatively for patent
grafts by measuring the lumen diameter of the graft (LGD)
distal to the arterial anastomosis and the lumendiameter at the
venous anastomosis (LVD). Three measurements were made
at each location and averaged. The percentage of stenosis was
determined at implant (day 0) and at euthanasia (day 3 or 28)
using the following equation: (LGD – LVD)/(LGD) 100.
Venous lumen diameter was determined by taking the
average of 3 to 4 measurements starting just distal from
the anastomotic site and along a 6-cm length of vein. The
average venous lumen diameter (VLD) for each image was
normalized by the corresponding LGD for that image. Late
venous luminal gain (VLG) was determined by comparison
of the venous lumen diameter after surgery (VLDday 0) to
that just before euthanasia (VLDeuth). Luminal gain was
calculated by dividing each venous diameter by the refer-
ence graft diameter (LGD) using the following equation:
VLG  (VLDeuth/LGDeuth) – (VLDday 0/LGDday 0). Data
from orthogonal images were averaged so that each animal
resulted in one data point for each analysis.
Tissue processing and staining. On postoperative
days 3 and 28, animals were euthanized with IV sodium
pentobarbital. The graft and associated vessels were perfu-
sion fixed in situ with phosphate-buffered saline, followed
by formalin. The anastomotic sites and surrounding tissue
were trimmed, embedded in paraffin, sectioned, mounted
on glass slides, and stained with hematoxylin and eosin
(H&E). Three 5-m sections were obtained through each
Fig 1. A, Schematic diagram of arteriovenous graft
direction of blood flow. PTFE, Polytetrafluoroethylen
endothelial cell/Gelfoam matrices at the venous site immarterial anastomosis at 1-mm intervals and also across eachvenous anastomosis. After the last venous anastomotic sec-
tion, five sections through the venous outflow tract at 2 to
3 mm intervals were obtained over an additional length of
15 mm of vein. Slides were read and interpreted by a
board-certified veterinary pathologist blinded to treatment
groups.
Histomorphologic findings were graded on a scale
from 1 through 4, depending upon severity (0  no
significant changes; 1minimal; 2mild; 3moderate;
4  severe; Appendix Table, online only). Histomorpho-
metric analysis was performed on Verhoeff stained sections
from the arterial and venous sites of patent grafts from
animals euthanized at 28 days. The intimal (I), medial (M)
and lumen (L) areas were measured using computerized
digital planimetry with an Olympus BX51 microscope, an
Olympus DP-70 digital camera (Olympus Melville, NY),
and customized software. The boundaries of each layer
(lumen, intima andmedia) were outlined and the computer
software determined the area (mm2) within each outlined
sector.
In anastomotic sections, which contained both vessel
and graft, the vessel and graft were measured separately.
Morphometric measurements were made by a board-
certified veterinary pathologist who was blinded to the
treatment groups. The extent of luminal occlusion and
intimal hyperplasia was determined by normalizing the
intimal area by the lumen [I/(IL)] ormedia area [I/(I
M)], respectively. Total vessel size and the extent of remod-
eling were assessed by measuring the area circumscribed by
the outer border of the external elastic lamina of the vessel.
MMP expression was localized in venous sections by
using antibodies specific for the precursor (pro) and acti-
vated forms of MMP-2 and MMP-9 (murine antihuman
MMP-2 or rabbit antihuman MMP-9, 1:250 dilution,
enous implant positioning. The arrows indicate the
Photograph after implantation of three porcine aortic
tely after arteriovenous graft creation.and v
e. B,Chemicon International, Inc, Temecula, Calif). At least six
poin
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specimen. For quantitative assessment of positive MMP
staining, randomly selected areas were imaged using an
Olympus BX60 microscope. Digital images were captured
and analyzed using Image-Pro Plus 6.0 software (Media
Cybernetics, Silver Spring, Md). Each area of interest was
highlighted and positive staining quantified by color seg-
mentation. The results were expressed as percentage of
positive area (positive area in mm2 over total area in mm2).
Quantitative assessment of positive staining was performed
by an observer who was blinded to the treatment groups.
Statistical analysis. All data are presented as mean 
standard error. Statistical analysis comparing treatment
groups used a nonparametric Mann-Whitney test per-
formed using GraphPad Prism 3.02 (GraphPad Software,
San Diego, Calif). A Pearson correlation determined the
relationship between lumen diameter and MMP expres-
sion. Values of P  .05 were considered significant.
RESULTS
Biologic effects of perivascular endothelial implants.
The number of PAE cells that could be recovered from
Gelfoam matrices increased exponentially from 1.25 to
Fig 2. Representative angiograms and measurements. A
significant changes in venous diameter or percentage o
obtained 28 days after surgery compared to baseline sho
aortic endothelial (PAE) cells and less stenosis at the ve
shows changes in venous lumen diameter 3 and 28 days
stenosis at 3 and 28 days after surgery. Data in B andC a
day 0; †P  .05 compared with control at the same time1.66 105cells/cm3 on day 0 to 10 to 16 105 cells/cm3at confluence. PAE cell/Gelfoam matrices were assayed for
TGF-1, TIMP-1, TIMP-2, NO, and HS production. Sig-
nificant levels of HS (1.33  0.23 g/mL), TGF-1 (507
 22 pg/mL), NO (2.1  0.40 mol/L), and TIMP-2
(9.3 0.96 ng/mL) per day were detected in conditioned
media collected from postconfluent in vitro cohorts. These
seline angiograms of control and treated grafts show no
nosis 3 days after surgery. Comparison of angiograms
eater venous luminal gain in veins treated with porcine
anastomotic site compared with control. B, Bar graph
surgery. C, Bar graph shows the average percentage of
sented with the standard error. *P .05 compared with
t.
Table I. Histopathologic characteristics of venous sites at
28 days
Characteristics* Control PAE cells
Intima area (mm2) 1.3  1.04 0.88  0.30
Media area (mm2) 4.04  0.69 6.66  2.37
Lumen area (mm2) 5.82  1.38 13.18  2.74†
EEL area (mm2) 11.16  1.97 20.72  1.51†
Luminal occlusion (ratio)‡ 0.18  0.10 0.06  0.02
Intimal thickening (ratio)§ 0.24  0.16 0.12  0.08
PAE, Porcine aortic endothelial; EEL, external elastic lamina.
*Measurements were averaged so that each animal resulted in 1 data point.
†P  .05 compared with control.
‡Luminal occlusion  I/(L  I); where I  intima, L  lumen, and M 
media.
§Intimal thickening  I/(I M); where I  intima and M  media., Ba
f ste
w gr
nous
after
re prelevels are similar to those produced from cells grown on
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not detected in conditioned media samples.
The pigs used in this study were randomly selected to
receive Gelfoam with or without PAE cells (control). All
incisions healed well and all animals gained weight
throughout the respective postoperative period. Five ani-
mals in each group were euthanized at 3 and 28 days. Two
control grafts and one PAE treated graft were occluded at
euthanasia on day 3. One control and one treated graft
were occluded at euthanasia on 28 day. All occlusions
occurred early ( first 7 days) and were not unexpected in
this model.
Analysis of angiograms of patent grafts obtained at
baseline and euthanasia revealed an increase in VLG at day
28 for veins treated with PAE cells compared with control
(1.8 0.58 vs 0.01 0.44, respectively). The treated veins
increased 2.8-fold in diameter, from 1.04  0.09 at day 0
to 2.9  0.56 at day 28 (P  .05), and control veins
remained essentially unchanged, from 1.28 0.13 at day 0
to 1.29  0.35 at day 28 (Fig 2). Veins treated with PAE
cell implants had a 2.3-fold increase in VLD compared with
control, which appeared to extend over the 4-cm length
covered by the implant and up to 2 cm beyond. No
significant VLG was observed in control or animals treated
with PAE cells at 3 days.
The cell-containing implants also reduced vein–graft
stenosis by 81%, from 45%  13% for control grafts to
8.5%  2.9% for grafts treated with PAE cells (P  .05) at
day 28. Morphometric analysis of the vein at the anasto-
motic and outflow sites (Table I) demonstrated similar
results. Veins treated with cell-containing implants had a
2.3-fold increase in lumen area compared with control (P
.05). In addition, total vessel area increased from 11.16 
1.97 mm2 for control to 20.72  1.51 mm2 for veins
treated with PAE cells (P  .05), suggesting greater posi-
tive remodeling in the treated veins. PAE cells/Gelfoam
also reduced venous luminal occlusion by 66% and intimal
thickening by 51% (Table I).
Morphometric analysis of graft sections at the venous
anastomotic site revealed little differences in pseudointima
(2.45  0.23 mm2 and 2.23  0.14 mm2) or lumen areas
(11.64  5.7 mm2 and 13.2  2.6 mm2) between control
and PAE cell implants, respectively, suggesting that most of
the benefits were localized to the native vessel. At 4 weeks
after implant, there was minimal stenosis and luminal oc-
clusion observed at the arterial sites and no obvious differ-
Table II. Average severity of inflammation, fibrosis and n
Inflammation†
Time (Days) Control PAE cells
3 (short term) 0.93  0.1 0.75  0.1 1
28 (long term) 1.0  0.2 0.7  0.09 3
*Average severity refers to severity of group/incidence, each animal represe
†Short term, primarily neutrophils; long term, macrophages and lymphocyt
‡P  .05 compared with control at the same time point.ences in vessel remodeling between groups (data not shown).Minimal inflammation was present in the adventitia of
the venous implant sites in animals from both groups at
days 3 and 28, with no significant differences between
control anastomoses and those treated with PAE cells
(Table II). Fibrosis was also present in the adventitia of
veins in animals from both groups at 3 and 28 days, with an
increase in fibrosis at 1 month consistent with the healing
process. Less fibrosis was noted in veins treated with PAE cells
compared with veins in control animals at 28 days (Table II).
Evidence of neovascularization was also observed in
both groups at both time points. Both acute and chronic
neovascularization was decreased in veins treated with PAE
cells compared with control (Table II, Fig 3). No signifi-
cant circumferential variation was seen in any of the sections
analyzed for histomorphology or histopathology. None-
to-minimal luminal inflammation was observed at 3 and 28
days in this model, and no difference was observed between
groups (data not shown).
Matrix metalloproteinase localization. Immuno-
histochemical analysis of MMP expression in the total
vessel, intima, media and adventitia 3 and 28 days after
surgery revealed reduced expression in veins treated with
PAE cells compared with control veins, with most of the
positive staining localized to the extracellular matrix. In the
control group, significant MMP-2 staining was observed in
the adventitia, media, and intima at day 3 (11.2%  1.0%,
4.4%  0.6% and 2.1%  0.2%, respectively), with most of
the staining located in the adventitia (Fig 4). Decreased
expression of MMP-2 was observed in the adventitia, me-
dia, and intima of vessels treated with PAE cells at day 3
(6.9% 1.2%, 2.3% 0.4%, and 0.8% 0.2%, respectively,
P .05). At 28 days, the amount of staining had decreased
in the adventitia (5.7%  0.9%) of control veins, but the
staining in the media and intima were still significantly
increased (4.9%  1.0% and 2.6%  0.8%, respectively)
compared with veins treated with PAE cells (1.3%  0.2%
and 0.3% 0.1%, respectively, P .05). A strong negative
correlation was observed between total MMP-2 expres-
sion and lumen diameter at 28 days (r  –0.80, P  .009;
Fig 4).
MMP-9 staining was less intense in both the control
and treated groups at both time points compared with
MMP-2 staining (Appendix Fig, online only). At 3 days
there was reduced staining in the adventitia of veins treated
with PAE cells compared with the control (P .05). At 28
cularization at the adventitial venous sites*
Fibroblasts/fibrosis Neovascularization
rol PAE cells Control PAE cells
0.2 1.0  0.06 1.2  0.2 0.6  0.08‡
0.2 2.3  0.2‡ 3.0  0.3 2.1  0.2‡
ne data point.
nimal neutrophils).eovas
Cont
.2 
.1 
nted o
es (midays, decreased MMP-9 expression was observed in the
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control (P  .05).
DISCUSSION
The major findings in this study are that the adventitial
application of endothelial implants significantly reduced
MMP-2 expression within the venous wall at 3 days and
increased venous lumen diameter and positive remodeling
at 28 days in porcine AVGs compared with control. The
data presented here provide further information on the
mechanism of action of the perivascular implants and AVG
failure. Positive remodeling is an important factor in the
success or failure of an AVG because the vein must accom-
modate arterial blood flow and pressure. Lumen diameter is
the functional parameter used in vascular clinical trials and
is not only determined by the degree of intimal thickening
but is also influenced by the overall change in vessel size due
to remodeling of the vessel wall. Therefore, in this study we
examined the role of perivascular PAE cells on venous
lumen size, remodeling, and vein–graft stenosis.
The mechanism of graft failure is a complex, multifac-
torial pathologic process that involves a combination of
many biologic events, and it is therefore unlikely that a
single agent aimed at any one process could prove success-
ful in treating the cause of AVG failure. This is indeed the
case, because despite success in animal models of AVG
stenosis,15-18 approaches to reduce clinical graft failure
have thus far proven unsuccessful.4 The endothelial cell
implants described here represent a novel approach to
addressing this problem. In addition to increasing venous
Fig 3. Representative photomicrographs of hematoxyli
on days 3 and 28. Increased neovascularization (arrows)
intimal formation occurred predominately at the venous
adventitia.lumen and vessel area and decreasing vascular stenosis,cell-containing implants also inhibited adventitial fibrosis at
28 days and neovascularization at 3 days and 28 days.
In recent years, the adventitia has emerged as a key
regulator of vascular remodeling.19 The adventitia consists
primarily of fibroblasts, which proliferate and migrate to-
ward the intima after vessel injury.8,20 An increase in ad-
ventitial fibrosis may constrict the injured vessel and con-
tribute to vascular remodeling and lumen loss.21
MMPs are necessary for the migration of adventitial
and medial cells into the neointima after vascular injury by
degrading extracellular matrix proteins.22 The upregula-
tion of MMP-2 and MMP-9 and down regulation of their
inhibitors, TIMPs, coincide with the formation of neoin-
tima and remodeling after vascular injury.23-25 Indeed, it
has been shown that adventitial expression of MMP-2
increases after vascular injury in porcine AVGs.26
In the present study, MMP-2 expression was reduced
in veins treated with PAE cells compared with control
veins. Most MMP-2 activity was localized to the adventitia
at day 3 and to the intima and media at 1 month. This is in
agreement with previous studies suggesting that increased
MMP activity may be necessary for cell migration to the
intima to occur.18,26 MMP-2 expression in the venous wall
correlated strongly with a decrease in lumen diameter at 28
days, suggesting that a potential mode of action of the
perivascular endothelial implants in this model may be to
modulate MMP-2 activity.
MMP proteolysis is also a critical component of neo-
vascularization,27 which has been implicated in the forma-
tion of stenosis and luminal narrowing.9,28 In particular,
eosin and Verhoeff elastin stained venous cross-sections
observed in control veins at 3 and 28 days. On day 28,
f the anastomosis. I, Intima;M,media; L, lumen; ADV,n and
was
side oMMP-2 plays an essential role in extracellular matrix-
ays.
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neovascularization was reduced in veins treated with im-
plants containing PAE cells compared with control veins.
Although adventitial inflammation has also been correlated
with negative vascular remodeling,7 minimal perivascular
inflammation was noted in this study with no significant
differences between groups. The absence of significant
adventitial and luminal inflammation may have been due to
the use of dexamethasone in this model.
Confluent endothelial cells release a variety of biologic
agents that in combination inhibit cell migration, prolifer-
ation, and intimal thickening.30-32 The benefit of using
Fig 4. Matrixmetalloproteinase-2 (MMP-2) localization
(M) of a control vein with significant MMP-2 expressio
endothelial (PAE) cells 3 days after surgery. Increased
compared with veins treated with PAE cells. I, Intima;
A significant decrease in MMP-2 staining was observed in
Reduced MMP-2 staining was also observed at 1 mon
compared with control. Data are presented with the stan
with control.C, Pearson correlation with 95% confidence
MMP-2 expression and lumen diameter of veins at 28 dperivascular implants compared with a single agent is theability to theoretically target multiple biologic responses to
injury rather than a single event:
● HS secreted by endothelial cells is a potent inhibitor of
SMC proliferation and migration as well as platelet
activation, adhesion, and thrombus formation.33,34
● TGF-1 inhibits SMC and fibroblast proliferation and
regulates the expression of MMPs.35,36
● TIMP-2 can form a tight 1:1 inhibitory complex with
MMP-2, but TIMP-2 is also known to inhibit cell
growth and angiogenesis.23,27,37
● Endothelial-derived NO is a potent vasodilator with
orcine jugular veins 3 and 28 days after surgery.A,Media
rows) compared with a vein treated with porcine aortic
-2 expression was also observed at 1 month in control
, adventitia. B, Quantification of MMP-2 localization.
s treated with PAE cells compared with control at 3 days.
the intima and media of veins treated with PAE cells
error. *P  .05 for treatment with PAE cells compared
val. A strong negative correlation was observed betweenin p
n (ar
MMP
ADV
vein
th in
dard
intermany functions within the vessel wall and its response
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MMP-2 and MMP-9 activities and increased TIMP
secretion.39
The lack of circumferential variation in the histopatho-
logic analysis of venous tissue suggests that the effects of the
implants or their factors, or both, are distributed circum-
ferentially throughout the blood vessel wall. The effects
rendered by the implants were determined to be due to the
presence of cells because sham matrices produced no ben-
efit. In previous porcine vascular injury models, we have
shown the presence of confluent endothelial cells within
the implants 3 days after implantation.13 By 28-days, al-
though cells can be found in the implant, there is substan-
tial cell loss that is partly due to in vivo degradation of the
gelatin matrix.11 However, the data presented here and
supported by previous studies indicate that the endothelial
implants, or factors secreted by the cells, may provide
control over the response to injury by influencing early
events such as MMP expression and neovascularization.
A limitation of the present study was that zymography
was not used, and therefore, the levels of active vs latent
MMP could not be assessed. Follow-up studies are needed
to address this issue. The animals used in this study were
young, healthy, and not uremic, and their grafts were not
accessed during the time course of the study; therefore, the
impact of additional risk factors associated with hemodial-
ysis patients were not assessed. However, the data pre-
sented here suggest that adventitial endothelial cell im-
plants may be useful in decreasing luminal narrowing in a
clinical setting. Indeed, arteriovenous graft and fistula trials
investigating endothelial implants in hemodialysis patients
are currently ongoing.
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Table. Grading criteria for histomorphologic findings
Grade
Criteria 0 1 2 3 4
Fibroblasts (per
40 HPF)
0 20 21-100 101-200  200
Fibrosis/fibroplasia
(adventitial)
Loose, normal
collagen
Compacted continuous
band 100 m or
focal 100 m
Compacted continuous
band 200 m or
focal 200 m
Compacted continuous
band 300 m or
discontinuous or
focally 300 m
Compacted
continuous
band 300
m
Neovascularization
(per 20 HPF)
0 Focal 5 vessels 6-15 vessels 16-25 vessels  25 vessels
and/or
diffuse
Cellularity* (cells
per 40 HPF)
0 20 21-100 101-200 200
HPF, High-powered field.
*By cell type (ie, neutrophils, macrophages).
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September 2007556.e2 Nugent et alFig. Matrix metalloproteinase-9 (MMP-9) localization in porcine jugular veins 3 and 28 days after surgery. A,
Adventitia (ADV) of a control vein shows increasedMMP-9 staining (arrows) 3 days after surgery compared with veins
treated with porcine aortic endothelial (PAE) cells at 3 days. Increased MMP-9 expression was also observed in the
intima (I) and adventitia at 1 month in veins treated with control Gelfoam compared with veins treated with PAE cells.
M, media; L, lumen. B, Quantification of MMP-9 localization presented with the standard error. Reduced MMP-9
expression was observed in the adventitia of veins treated with PAE cells compared with control at 3 days. A decrease
in MMP-9 expression was also observed in the intima and adventitia of PAE treated veins compared to control at 1
month. *P  .05 for veins treated with PAE cells compared with control.
